I sent another email (below) to IR. They are almost certain not to respond, but if they do, I'll post it. Either way, nice to let off some steam.
Dear Investor Relations,
I'll be posting this email and any response, or lack thereof, on Stockhouse. You may not be aware of this website, but it is where your retail bag-holders go to commiserate over the performance of this company.
It has now become public knowledge that new pharmaceutical pricing legislation is under consideration in the UK. Will the company being sharing any information about the impact this will have on CXR's EBITDA, or will you leave that to the short sellers?
The shenanigans over the CEO's supposed appearance, and then mystery cancellation, from BNN programming creates further uncertainty. Us bag-holders are starved for information from the company. We were all hopeful that he would show-up and tell us something about some current initiatives and whether he has any plan whatsoever to overcome the company's crippling interest payments and competition from all of the more nimble pharmaceutical companies that are out there.
You may wish to confirm for the shareholders that the CEO still has a pulse, that he is still working on a strategic transaction, and explain whether CXR will be evolving it plan in the face of new regulations and competition.
All the best from one of your most loyal bag-holders!